Campylobacter with high RCP level need treatment treat

In patients with Campylobacter infection and elevated C-reactive protein (CRP) levels, treatment should be guided primarily by the clinical presentation and the presence of systemic or extraintestinal complications. For typical Campylobacter enteritis, which is often self-limiting, antibiotic therapy is not always required; however, in severe, prolonged, or complicated infections—especially in immunocompromised patients—targeted antibiotic treatment is recommended. Elevated CRP reflects an active inflammatory or infectious process and supports consideration of antimicrobial therapy if symptoms are significant or systemic involvement is suspected.

Specifically, empirical antibiotic choices include macrolides (such as azithromycin) which are commonly used; however, interactions with other medications such as colchicine should be considered. Fluoroquinolones like levofloxacin can be used as alternatives, particularly when macrolide use is contraindicated or when resistance is a concern. Treatment duration is typically short, guided by clinical response and susceptibility testing if available.

For patients presenting with extraintestinal manifestations, such as the reported case of Campylobacter jejuni-associated perimyocarditis, management includes antibiotic therapy alongside supportive and guided management of the cardiac condition (e.g., colchicine for pericarditis and guideline-directed medical therapy for heart failure). Nonsteroidal anti-inflammatory drugs are generally avoided in myocarditis due to potential for myocyte injury. Close follow-up and imaging (e.g., echocardiogram and cardiac magnetic resonance when available) are recommended to monitor resolution.

In immunocompromised patients with hypogammaglobulinemia, Campylobacter infections can be more severe and recurrent. Stool screening and detection via culture or PCR should prompt consideration of appropriate antibiotic therapy, as spontaneous clearance may be impaired despite immunoglobulin replacement. Elevated faecal calprotectin and CRP in these patients support active infection rather than colonization, reinforcing the need for treatment, often requiring prolonged or combination antibiotic regimens guided by susceptibility profiles.

Therefore, recommended treatment in patients with Campylobacter infection and elevated CRP involves judicious use of antibiotics tailored to severity, underlying immune status, and clinical manifestations; macrolides or fluoroquinolones are preferred, with careful consideration of drug interactions and underlying conditions.